Indication
CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein C deficiency.
Loading your page…
Loading your page…
Purpura Fulminans;Protein C Deficiency
Marketing Authorisation Holder: Takeda Manufacturing Austria AG
EMA Authorisation: 16/07/2001
INN: human protein C
AI Drug & Interaction Analysis
Free account required
Ask Osler about Ceprotin: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.